Abstract
AEterna is developing AE-941, an angiogenesis inhibitor derived from the ultrafiltration of liquid shark cartilage, with matrix metalloprotease (MMP)-2, MMP-9 and vascular endothelial growth factor inhibitory properties, for the potential treatment of non-small-cell lung cancer.
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Carcinoma, Non-Small-Cell Lung / metabolism
-
Clinical Trials as Topic / statistics & numerical data
-
Drugs, Investigational / chemistry
-
Drugs, Investigational / pharmacology
-
Drugs, Investigational / therapeutic use*
-
Humans
-
Lung Neoplasms
-
Tissue Extracts / chemistry
-
Tissue Extracts / pharmacology
-
Tissue Extracts / therapeutic use*
Substances
-
Antineoplastic Agents
-
Drugs, Investigational
-
Tissue Extracts
-
shark cartilage extract